result of new information, future events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews

For Novartis multimedia content, please visit https://www.novartis.com/news/media-library

For questions about the site or required registration, please contact media.relations@novartis.com.

References 


   1. Anderton RS and Mastaglia FL. Expert Rev Neurother. 2015;15(8):895--908. 
 
   2. Finkel RS, McDermott MP, Kaufmann P. et al. Observational study of spinal 
      muscular atrophy type I and implications for clinical trials. Neurology. 
      2014;83(9):810-7. 
 
   3. Lorson CL, Rindt H, Shababi M. Spinal muscular atrophy: mechanisms and 
      therapeutic strategies. Hum Mol Genet. 2010;(15):R111-8. 
 
   4. Darras BT, Finkel RS. "Natural history of spinal muscular atrophy." In: 
      Sumner CJ, Paushkin S, Ko CP, eds. Spinal Muscular Atrophy: Disease 
      Mechanisms and Therapy, 2nd ed. London, UK: Academic 
      Press/Elsevier;2017:399--421.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com 


 
Richard Jarvis                        Farah Bulsara Speer 
 Novartis External Communications      SVP, Corporate Communications, Novartis Gene Therapies 
 +41 79 584 23 26 (mobile)             +1 312 543 2881 (mobile) 
 richard.jarvis@novartis.com           farah.speer@novartis.com 
 Julie Masow 
 Novartis US External Communications 
 +1 862 579 8456 
 julie.masow@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com 


 
Central                                 North America 
Samir Shah             +41 61 324 7944  Sloan Simpson  +1 862 345 4440 
Thomas Hungerbuehler   +41 61 324 8425  Alina Levchuk  +1 862 778 3372 
Isabella Zinck         +41 61 324 7188  Parag Mahanti  +1 973-876-4912

(END) Dow Jones Newswires

August 03, 2021 01:15 ET (05:15 GMT)